Numis Reconfirms Whitbread PLC (LON:WTB) As “Hold”; Has Price Target Of GBX 4300.00; Conatus Pharmaceuticals Has 1.1 Sentiment

April 16, 2018 - By Louis Casey

Whitbread PLC (LON:WTB) Logo

London: In an analyst note issued to clients and investors on Monday, 16 April, Numis reaffirmed their “Hold” rating on shares of Whitbread PLC (LON:WTB). They currently have a GBX 4300.00 TP on the company. Numis’s target would suggest a potential upside of 2.60% from the company’s current stock price.

Conatus Pharmaceuticals Inc (CNAT) investors sentiment decreased to 1.1 in 2017 Q4. It’s down -0.73, from 1.83 in 2017Q3. The ratio dived, as 34 investment managers opened new and increased positions, while 31 sold and trimmed positions in Conatus Pharmaceuticals Inc. The investment managers in our database reported: 11.71 million shares, up from 10.89 million shares in 2017Q3. Also, the number of investment managers holding Conatus Pharmaceuticals Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 14 Reduced: 17 Increased: 23 New Position: 11.

Whitbread PLC operates hotels, restaurants, and coffee shops. The company has market cap of 7.71 billion GBP. The firm operates through two divisions, Premier Inn & Restaurants and Costa. It has a 16.33 P/E ratio. It operates approximately 760 hotels with 68,000 rooms in the United Kingdom, the Middle East, and Germany, as well as hotels under the Premier Inn brand name; hotels under the hub by Premier Inn brand name in the United Kingdom; and restaurants under the Brewers Fayre, Beefeater Grill, and Table Table brands.

The stock increased 6.68% or GBX 262.8789 during the last trading session, reaching GBX 4197.8789. About 615,704 shares traded. Whitbread PLC (LON:WTB) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 27 analysts covering Whitbread PLC (LON:WTB), 13 have Buy rating, 3 Sell and 11 Hold. Therefore 48% are positive. Whitbread PLC has GBX 6000 highest and GBX 3200 lowest target. GBX 4412.21’s average target is 5.11% above currents GBX 4197.8789 stock price. Whitbread PLC had 278 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Citigroup on Wednesday, October 25 with “Sell”. The stock has “Outperform” rating by Credit Suisse on Thursday, September 17. Shore Capital maintained the stock with “Buy” rating in Thursday, March 1 report. The company was maintained on Wednesday, June 22 by Deutsche Bank. Barclays Capital maintained Whitbread PLC (LON:WTB) on Thursday, March 29 with “Equal Weight” rating. The company was maintained on Friday, October 20 by Deutsche Bank. The company was maintained on Friday, January 12 by Citigroup. The stock has “Overweight” rating by JP Morgan on Wednesday, June 22. Nomura maintained Whitbread PLC (LON:WTB) on Monday, March 7 with “Buy” rating. On Tuesday, August 22 the stock rating was upgraded by Goldman Sachs to “Sell”.

Mpm Asset Management Llc holds 3.89% of its portfolio in Conatus Pharmaceuticals Inc. for 2.10 million shares. Courage Capital Management Llc owns 200,000 shares or 0.66% of their US portfolio. Moreover, Acadian Asset Management Llc has 0.02% invested in the company for 815,628 shares. The France-based Axa has invested 0.01% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 136,300 shares.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $115.73 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on May, 3. They expect $-0.17 EPS, down 21.43% or $0.03 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 13.33% negative EPS growth.

Ratings analysis reveals 100% of Conatus Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Conatus Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5.0 while the high is $18.0. The stock’s average target of $11.50 is 198.70% above today’s ($3.85) share price. CNAT was included in 2 notes of analysts from November 9, 2016. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, November 9. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 20 report.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>